Additional Information Additional Information Development Pipeline as at 31 December 2014 Phase III Pivotal Phase II Registration NMEs and significant additional indications Submission dates shown for assets in Phase III and beyond.
As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
Date Estimated Filing Commenced Compound Mechanism Area Under Investigation Phase US EU Japan China Cardiovascular and Metabolic diseases 1 Brilinta Brilique ADP receptor antagonist arterial thrombosis Launched Launched Filed Launched # Epanova omega-3 free fatty acids  Approved 2017 2019 2 Farxiga Forxiga SGLT-2 inhibitor Type 2 diabetes Launched Launched Launched Filed 3 Myalept leptin analogue lipodystrophy Launched Q4 2015 N A # roxadustat hypoxia-inducible factor prolyl anaemia in CKD ESRD Q3 2014 2018 N A N A H2 2016 hydroxylase inhibitor Oncology AZD9291 EGFR tyrosine kinase inhibitor advanced EGFRm T790M NSCLC Q2 2014 Q2 2015 Q2 2015 Q3 2015 2017 Caprelsa VEGFR EGFR tyrosine kinase medullary thyroid cancer Launched Launched Filed Filed inhibitor with RET kinase activity # MEDI4736 PACIFIC anti-PD-L1 MAb stage III NSCLC Q2 2014 2017 2020 2020 # MEDI4736 ATLANTIC anti-PD-L1 MAb 3rd line NSCLC Q1 2014 H1 2016 2017 2017 # moxetumomab pasudotox anti-CD22 recombinant hairy cell leukaemia Q2 2013 2018 2018 immunotoxin 4 Lynparza olaparib PARP inhibitor BRCAm PSR ovarian cancer Launched Approved Lynparza olaparib SOLO-1 PARP inhibitor 1st line BRCAm ovarian cancer Q3 2013 2017 2017 2017 2018 Lynparza olaparib SOLO-2 PARP inhibitor BRCAm PSR ovarian cancer Q3 2013 H1 2016 H1 2016 H2 2016 2018 Lynparza olaparib GOLD PARP inhibitor 2nd line gastric cancer Q3 2013 2017 2018 Lynparza olaparib OlympiA PARP inhibitor adjuvant breast cancer Q2 2014 2020 2020 2020 2021 Lynparza olaparib OlympiAD PARP inhibitor metastatic breast cancer Q2 2014 2016 2016 2016 2018 # selumetinib SELECT-1 MEK inhibitor 2nd line KRAS NSCLC Q4 2013 2017 2017 # selumetinib ASTRA MEK inhibitor differentiated thyroid cancer Q3 2013 2017 2017 # selumetinib SUMIT MEK inhibitor uveal melanoma Q2 2014 Q4 2015 Q4 2015 tremelimumab anti-CTLA-4 MAb mesothelioma Q2 2014 H1 2016 H2 2016 Respiratory, Inflammation and Autoimmunity # benralizumab CALIMA anti-IL-5R MAb severe asthma Q4 2013 H2 2016 H2 2016 SIROCCO ZONDA BORA # benralizumab TERRANOVA anti-IL-5R MAb COPD Q3 2014 2018 2018 GALATHEA # brodalumab AMAGINE-1,2, 3 anti-IL-17R MAb psoriasis Q3 2012 2015 2015 # brodalumab AMVISION-1,2 anti-IL-17R MAb psoriatic arthritis Q1 2014 5 6 lesinurad CLEAR 1,2 CRYSTAL selective uric acid reabsorption chronic treatment of patients Q4 2011 Q1 2015 Filed inhibitor SURI with gout PT003 GFF LAMA LABA COPD Q2 2013 Q3 2015 H1 2016 2017 2017 PT001 GP LAMA COPD Q2 2013 tralokinumab STRATOS 1,2 anti-IL-13 MAb severe asthma Q3 2014 2018 2018 2018 TROPOS Infection # CAZ AVI RECLAIM cephalosporin beta lactamase serious infections Q1 2012 N A Q1 2015 H2 2016 inhibitor # CAZ AVI REPROVE cephalosporin beta lactamase hospital-acquired pneumonia Q2 2013 N A 2017 2018 inhibitor  pneumonia # Zinforo extended spectrum pneumonia skin infections N A Launched N A Filed cephalosporin with affinity to penicillin-binding proteins Neuroscience #7 Movantik Moventig oral peripherally-acting mu-opioid opioid-induced constipation Approved Approved receptor antagonist # Partnered product.
Registrational Phase II III study.
Filing is the responsibility of the partner.
1 Brilinta in the US: Brilique in rest of world.
2 Farxiga in the US: Forxiga in rest of world.
3 Divested to Aegerion effective 9 January 2015.
4 Launched simultaneously with US approval December 2014.
5 Submission made in US in December 2014, acceptance anticipated Q1 2015.
7 Movantik in the US: Moventig in EU.
AstraZeneca Annual Report and Form 20-F Information 2014 197 Additional Information Development Pipeline continued Phases I and II NMEs and significant additional indications Date Estimated Filing Commenced Compound Mechanism Area Under Investigation Phase Phase US EU Japan China Cardiovascular and Metabolic diseases # 1 tenapanor AZD1722 NHE3 inhibitor ESRD-Pi CKD with T2DM II Q1 2013 AZD4901 hormone modulator polycystic ovarian syndrome II Q2 2013 MEDI6012 LCAT ACS I Q1 2012 MEDI8111 Rh-factor II trauma bleeding I Q1 2014 Oncology # AZD1775 WEE-1 inhibitor ovarian cancer II Q4 2012 AZD2014 mTOR serine threonine kinase solid tumours II Q1 2013 inhibitor AZD4547 FGFR tyrosine kinase inhibitor solid tumours II Q4 2011 # MEDI-551 anti-CD19 MAb CLL DLBCL II Q1 2012 # MEDI-573 anti-IGF MAb metastatic breast cancer II Q2 2012 Lynparza olaparib PARP inhibitor prostate cancer II Q3 2014 # selumetinib MEK inhibitor 2nd line KRASNSCLC II Q1 2013 # AZD5363 AKT kinase inhibitor breast cancer II Q1 2014 # MEDI4736 anti-PD-L1 MAb solid tumours II Q3 2014 # moxetumomab pasudotox anti-CD22 recombinant pALL II Q3 2014 immunotoxin # AZD6094 volitinib MET tyrosine kinase inhibitor papillary renal cell carcinoma II Q2 2014 AZD9291 EGFR tyrosine kinase inhibitor 1st line advanced EGFRm II Q4 2014 NSCLC AZD3759 EGFR tyrosine kinase inhibitor advanced EGFRm NSCLC I Q4 2014 # AZD5312 androgen receptor inhibitor solid tumours I Q2 2014 AZD6738 ATR serine threonine kinase solid tumours I Q4 2013 inhibitor AZD8186 PI3 kinase beta inhibitor solid tumours I Q2 2013 AZD8835 PI3 kinase alpha inhibitor solid tumours I Q4 2014 # AZD9150 STAT3 inhibitor haematological malignancies I Q1 2012 # AZD9291 MEDI4736 or EGFR tyrosine kinase inhibitor advanced EGFRm NSCLC I Q3 2014 # # selumetinib or volitinib anti-PD-L1 or MEK inhibitor TATTON or MET tyrosine kinase inhibitor AZD9496 selective oestrogen receptor ER breast cancer I Q4 2014 downregulator SERD # MEDI4736 after AZD9291 or anti-PD-L1 MAb EGFR NSCLC I Q3 2014 # Iressa or selumetinib tyrosine kinase inhibitor or MEK docetaxel or tremelimumab inhibitor or anti-CTLA-4 MAb # MEDI-565 anti-CEA BiTE MAb solid tumours I Q1 2011 # MEDI0639 anti-DLL-4 MAb solid tumours I Q2 2012 MEDI0680 anti-PD-1 MAb solid tumours I Q4 2013 # MEDI3617 anti-ANG-2 MAb solid tumours I Q4 2010 # MEDI4736 anti-PD-L1 MAb various cancers I Q3 2014 # MEDI4736 MEDI0680 anti-PD-L1 MAb anti-PD-1 solid tumours I Q2 2014 MAb # # MEDI4736 MEDI6469 anti-PD-L1 MAb murine solid tumours I Q3 2014 OX40 agonist # MEDI4736 dabrafenib anti-PD-L1 MAb BRAF melanoma I Q1 2014 2 trametinib inhibitor MEK inhibitor # MEDI4736 Iressa anti-PD-L1 MAb EGFR NSCLC I Q2 2014 tyrosine kinase inhibitor # MEDI4736 tremelimumab anti-PD-L1 MAb antisolid tumours I Q4 2013 CTLA-4 MAb # MEDI-551 MEDI0680 anti-CD19 MAb anti-PD-1 DLBCL I Q4 2014 MAb # 3 MEDI-551 rituximab anti-CD19 MAb anti-CD20 haematological malignancies I Q2 2014 MAb # MEDI6383 OX40 agonist solid tumours I Q3 2014 # MEDI6469 murine OX40 agonist solid tumours I Q1 2006 # MEDI6469 tremelimumab murine OX40 agonist solid tumours I Q4 2014 anti-CTLA-4 MAb 198 AstraZeneca Annual Report and Form 20-F Information 2014 Additional Information Date Estimated Filing Commenced Compound Mechanism Area Under Investigation Phase Phase US EU Japan China Respiratory, Inflammation and Autoimmunity AZD0548 LABA asthma COPD II Q4 2007 #4 AZD2115 MABA COPD II Q2 2012 AZD7624 inhaled P38 inhibitor COPD II Q4 2014 # AZD9412 inhaled interferon asthma COPD II Q1 2010 # anifrolumab anti-IFN-alphaR MAb SLE II Q1 2012 # brodalumab anti-IL-17R MAb asthma II Q2 2013 # mavrilimumab anti-GM-CSFR MAb rheumatoid arthritis II Q1 2010 # MEDI2070 anti-IL-23 MAb Crohns disease II Q1 2013 # MEDI7183 anti-a4b7 MAb Crohns disease ulcerative II Q4 2012 colitis # MEDI9929 anti-TSLP MAb asthma II Q2 2014 PT010 LAMA LABA ICS COPD II Q2 2014 RDEA3170 selective uric acid reabsorption chronic management of II Q3 2013 inhibitor SURI hyperuricaemia in patients with gout # sifalimumab anti-IFN-alpha MAb SLE II Q3 2008 tralokinumab anti-IL-13 MAb IPF II Q4 2012 # AZD1419 TLR9 agonist asthma I Q3 2013 AZD7594 inhaled SGRM asthma COPD I Q3 2012 AZD8999 MABA COPD I Q4 2013 # MEDI-551 anti-CD19 MAb multiple sclerosis I Q3 2012 MEDI4920 anti-CD40L-Tn3 fusion protein primary Sjgrens syndrome I Q2 2014 # MEDI5872 anti-B7RP1 MAb SLE I Q4 2008 Infection AZD0914 GyrAR serious bacterial infections II Q4 2014 AZD5847 oxazolidinone anti-bacterial tuberculosis II Q4 2012 inhibitor # CXL beta lactamase inhibitor MRSA II Q4 2010 cephalosporin MEDI4893 MAb binding to S. aureus toxin hospital-acquired pneumonia II Q4 2014 serious S. aureus infection # ATM AVI monobactam beta lactamase targeted serious bacterial I Q4 2012 inhibitor infections MEDI-550 pandemic influenza virus pandemic influenza prophylaxis I Q2 2006 vaccine MEDI-559 paediatric RSV vaccine RSV prophylaxis I Q4 2008 MEDI3902 anti-Psl PcrV pseudomonas I Q3 2014 MEDI7510 RSV sF GLA-SE prevention of RSV disease in I Q2 2014 older adults # MEDI8897 anti-RSV MAb-YTE passive RSV prophylaxis I Q2 2014 Neuroscience 5 AZD3241 myeloperoxidase inhibitor multiple system atrophy II Q2 2012 # AZD3293 beta-secretase inhibitor Alzheimers disease II Q4 2014 AZD5213 histamine-3 receptor Tourettes syndrome II Q4 2013 antagonist neuropathic pain AZD8108 NMDA antagonist suicidal ideation I Q4 2014 MEDI1814 anti-amyloid beta MAb Alzheimers disease I Q2 2014 # Partnered product.
1 Fluid retention indication for tenapanor terminated in Q2 2014.
2 MedImmune-sponsored study in collaboration with GSK.
3 MedImmune-sponsored study in collaboration with Genentech.
4 Development on hold pending further pre-clinical evaluation.
5 Multiple system atrophy is now the lead indication for this molecule.
AstraZeneca Annual Report and Form 20-F Information 2014 199 Additional Information Development Pipeline continued LCM projects Date Estimated Filing Commenced Compound Mechanism Area Under Investigation Phase US EU Japan China Cardiovascular and Metabolic diseases 1 Brilinta Brilique EUCLID ADP receptor antagonist outcomes study in patients with Q4 2012 2017 2017 2017 2018 peripheral artery disease 1 Brilinta Brilique HESTIA ADP receptor antagonist prevention of vaso-occlusive crises Q4 2014 2020 2020 in paediatric patients with sickle cell disease 1 Brilinta Brilique PEGASUSADP receptor antagonist outcomes study in patients with Q4 2010 Q2 2015 Q2 2015 Q4 2015 2017 TIMI 54 prior MI 1 Brilinta Brilique SOCRATES ADP receptor antagonist outcomes study in patients with Q1 2014 H1 2016 H1 2016 H2 2016 2017 stroke or TIA 1 Brilinta Brilique THEMIS ADP receptor antagonist outcomes study in patients with Q1 2014 2017 2017 2018 2018 Type 2 diabetes and CAD, but without a previous history of MI or stroke Bydureon Dual Chamber Pen GLP-1 receptor agonist Type 2 diabetes Launched Approved Filed Bydureon EXSCEL GLP-1 receptor agonist Type 2 diabetes outcomes study Q2 2010 2018 2018 2018 Bydureon weekly suspension GLP-1 receptor agonist Type 2 diabetes Q1 2013 Q4 2015 Q4 2015 Epanova STRENGTH omega-3 free fatty acids outcomes study in statin-treated Q4 2014 2020 2020 2020 2020 patients at high CV risk, with persistent  plus low HDL-cholesterol 2 Farxiga Forxiga SGLT-2 inhibitor Type 2 diabetes outcomes study Q2 2013 2020 2020 DECLARE-TIMI 58 2 Farxiga Forxiga SGLT-2 inhibitor Type 1 diabetes Q4 2014 2018 2017 2018 3 Kombiglyze XR Komboglyze DPP-4 inhibitor metformin FDC Type 2 diabetes Launched Launched Filed Onglyza SAVOR-TIMI 53 DPP-4 inhibitor Type 2 diabetes outcomes study Q2 2010 Filed Launched 2015 4 saxagliptin dapagliflozin FDC DPP-4 inhibitor Type 2 diabetes Q2 2012 Q1 2015 Q2 2015 SGLT-2 inhibitor FDC 5 Xigduo XR Xigduo SGLT-2 inhibitor metformin FDC Type 2 diabetes Launched Launched Oncology Caprelsa VEGFR EGFR tyrosine kinase differentiated thyroid cancer Q2 2013 H1 2016 H1 2016 H1 2016 inhibitor with RET kinase activity Faslodex FALCON oestrogen receptor antagonist 1st line hormone receptor five Q4 2012 H2 2016 H2 2016 H2 2016 H2 2016 advanced breast cancer Respiratory, Inflammation and Autoimmunity Duaklir Genuair LAMA LABA COPD Approved Symbicort SYGMA-1 ICS LABA as needed use in mild asthma Q4 2014 N A 2018 6 Symbicort ICS LABA Breath Actuated Inhaler asthma COPD Neuroscience # Diprivan sedative and anaesthetic conscious sedation N A Launched Filed Launched Gastrointestinal Entocort glucocorticoid steroid Crohns disease ulcerative colitis Launched Launched Q3 2015 N A # linaclotide GC-C receptor peptide agonist irritable bowel syndrome with N A N A N A Q4 2015 constipation IBS-C Nexium proton pump inhibitor refractory reflux esophagitis Filed Nexium proton pump inhibitor stress ulcer prophylaxis 2017 Nexium proton pump inhibitor paediatrics Launched Launched H2 2016 3 5 # Partnered product.
Kombiglyze XR in the US: Komboglyze in the EU.
Xigduo XR in the US: Xigduo in the EU.
1 4 6 Brilinta in the US: Brilique in rest of world.
Submission made in US in December 2014, acceptance Development of a new BAI device is ongoing.
Discontinued projects between 1 January and 31 December 2014 NME LCM projects Compound Reason for Discontinuation Area Under Investigation NME AZD1208 Safety efficacy haematological malignancies NME AZD1979 Safety efficacy obesity NME AZD4721 Safety efficacy COPD NME AZD5069 Safety efficacy asthma NME AZD6423 Safety efficacy suicidal ideation # NME AZD8848 Safety efficacy asthma # NME MEDI8968 Safety efficacy COPD HS NME MEDI9287 Economic avian influenza LCM Iressa IMPRESS Safety efficacy treatment beyond progression # Partnered product.
200 AstraZeneca Annual Report and Form 20-F Information 2014
